Methods for analysis of GWAS summary statistics have encouraged data sharing and democratised the analysis of different diseases. Ideal validation for such methods is application to simulated data, where some "truth" is known. As GWAS increase in size, so does the computational complexity of such evaluations; standard practice repeatedly simulates and analyses genotype data for all individuals in an example study. We have developed a novel method based on an alternative approach, directly simulating GWAS 1 summary data, without individual data as an intermediate step. We mathematically derive the expected statistics for any set of causal variants and their effect sizes, conditional upon control haplotype frequencies (available from public reference datasets). Simulation of GWAS summary output can be conducted independently of sample size by simulating random variates about these expected values. Across a range of scenarios, our method,
Background
The genome wide association study design is now more than a decade old , and the size of GWAS cohorts has continued to grow, from 1000s to, now, 100,000s of individuals. Given the competing demands of open science and privacy concerns (P3G Consortium et al., 2009) , it has become standard to share data in the form of summary statistics (allelic effect sizes and standard errors, or simply p values) more readily than the full genotype data. A wealth of methods have been developed to operate directly on the summary statistics, from for fine mapping of genetic causal variants (e.g. PAINTOR (Kichaev et al., 2014) , CAVIARBF (Chen et al., 2015) and JAM (Newcombe et al., 2016) ) to (co-)heritability estimation (Bulik-Sullivan et al., 2015) and integration of GWAS results from different traits (Giambartolomei et al., 2014; Zhu et al., 2016) . Such methods are often derived through approximating a multivariate linear regression likelihood by incorporating information about correlation structures (linkage disequilibrium, LD) from reference populations. While GWAS of binary traits (eg case-control data) typically adopt a logistic regression approach to correctly model the increase in risk on the log odds scale, these summary statistic methods, often originally derived for linear regression models, have been applied to both quantitative and binary data.
2 As Biobank-sized datasets come to fruition, such summary statistic methods are likely to become even more important, since, for such large numbers of samples, operating on the complete genotype data matrices for efforts such as Bayesian fine mapping of causal variants is computationally prohibitive. Indeed, GWAS summary statistics for multiple traits from UK-Biobank have already been made freely available (Canela-Xandri et al., 2017) . Although for speed these are generated by linear regression on 0/1 coded outcome variables, methods exist to also convert these to log odds ratios in the case of binary data (Lloyd-Jones et al., 2018) .
While Biobanks tend to adopt a cohort design, meta-GWAS studies continue to over-sample cases compared to controls, in order to increase the available power, and are now exceeding 100,000 cases and controls in single studies (Michailidou et al., 2017) .
The gold standard for evaluating performance of summary statistic methods is through analysis of simulated data, allowing inference to be compared to a known "truth". GWAS simulators typically proceed by adding phenotypes to a sample of genotype data that is either simulated or from a reference population ("forward simulation") or by simulating or sampling genotype data conditional on a supposed distribution of phenotypes, typically used for casecontrol data structures ("conditional simulation"). Forward approaches in particular can be used very flexibly for generating multiple (quantitative) phenotypes, a design also common to Biobank datasets (Meyer and Birney, 2018) . However, conditional approaches are generally required for case-control data, because typical GWAS designs recruit cases disproportionately to their frequency in the population in order to increase power. Simulation options in this case are more limited because the problem is mathematically harder. For single causal variant scenarios, resampling from a reference population conditional on allele frequencies at a target variant may be used. For more complicated causal models, involving multiple variants potentially in LD, GWAsimulator (Li and Li, 2008) , TriadSim (Shi et al., 2018) or HAPGEN (Su et al., 2011) can very efficiently simulate haplotypes for cases and controls in small genomic regions. In particular, by incorporating mutations and recombinations, HAPGEN can simulate large populations with only a few hundred reference haplotypes. However, the generation of GWAS summary statistics, eg using SNPTEST (Marchini et al., 2007) , requires analysis of the individual level data which can be slow, particularly for logistic models which require iterative optimization at each SNP.
The general approach of simulating both genotype and phenotype on an individual level cannot scale well for Biobank-scale or large meta-GWAS situations, because of the number of individuals required. It is also potentially wasteful -the individual level data are not required when the goal is to evaluate methods that work on summary statistics.
Here, we present an alternative approach, which simulates summary statistics directly, without needing to ever generate genotype data. It scales as a function of the number of SNPs, but is constant with regards to the number of samples, thus making it ideally designed for simulation of summary statistics for large case-control studies.
Results

Overview of our approach
We first introduce the mathematical calculations which underpin our method. Given a causal model specifying which SNPs are causal and their effects on disease in the form of odds ratios, and reference data on allele and haplotype frequencies in controls, we calculate the expected Z score under an additive model at each SNP from a Cochran Armitage score test. (Cochran Armitage score tests have been used for GWAS because of their computational simplicity, requiring no iterative maximisation procedure, and because they allow for additive, dominant or recessive coding, although additive coding is the most commonly used (Sasieni, 1997) ).
Simulated Z scores can then be derived by multivariate normal simulation using standard software. This suffices in the case where the summary statistic methods to be used work upon Z scores alone. However, when log odds ratios and their standard errors are required, we appeal to the asymptotic similarity of score tests and Wald tests, and simulate standard errors under the causal model. Together with simulated Z scores, we can then back-calculate the log odds ratios as the product of simulated Z scores and standard errors. An outline 4 description of our calculations follows; full details are given in the Appendix.
Let Y i ∈ {0, 1} denote the indicator of disease status for the ith of N individuals sampled according to case-control status (N 1 cases, Y i = 1; N 0 controls, Y i = 0). Let n be the total number of SNPs. For any SNP X, write G X i for its genotype coding ∈ {0, 1, 2} at sample i. Then, for the commonly used Cochran-Armitage score test, the Z-Score at SNP X is computed as:
Write W = (W 1 , ..., W m ) T for the vector of causal SNPs and γ = (γ 1 , ..., γ m ) T for their log odds ratios of effect. We assume that Y i given G W i can be modelled as a binomial logistic regression:
where P sam () denotes that this is the probability within the GWAS sample and γ 0 is chosen such that P sam (Y i = 1) = N 1 N . The conditioning is required because allele frequencies vary between cases and controls at causal variants and those in LD with them, meaning the overall allele frequencies in our sample differ from those in the population as a whole. By specifically distinguishing between P sam () and the more general P(), we can condition on having chosen N 0 cases and N 1 controls and thus perform the conditional simulation needed for case-control studies.
By conditioning upon the values of G W and Y , we obtain the expected value of U X , the covariance between G X and Y :
and V X is the variance of G X . As V X is a variance, a natural model is an inverse gamma distribution, V X ∼ Γ −1 (α, β). By similar 5 conditioning upon G W and Y , we show that the parameters of this distribution are
(the derivation of this and expressions for the first two moments of V X are given in the Appendix). This means we can either simulate V X from its distribution or calculate
so that, to a first order approximation,
Putting this together, we can now calculate the expected Z score, Z E , across a set of SNPs, given a causal model and some phased reference data with which to calculate the probabilities in (1). Note that the computational complexity of this calculation is independent of both disease frequency and the number of samples required.
For some applications, the expected Z Score may suffice. However, note that the expected GWAS p value is not the p value associated with the expected Z score. Instead, we must simulated "observed" GWAS results which vary randomly about Z E , with variance 1, such that the correlation between the Z score at two SNPs is equal to the correlation between their genotypes (Burren et al., 2014) . It is hence computationally simple to simulate multiple realisations of GWAS Z scores as Z * ∼ MVN(Z E , Σ), where Σ is a matrix describing correlation between SNPs for the region, again estimated from the reference panel.
To generate log odds ratios, γ, and their standard errors, σ, we appeal to the asymptotic similarity of Wald tests from a logistic regression model to the Cochran Armitage score test, and the result that the variance of the score statistic U X is the inverse of the variance of the estimated γ, under the null (McCullagh and Nelder, 1983) . Thus, we simulate V * X ∼ 6 Inverse Gamma(α, β) with (α, β) given by (2,3) and hence V (U X ) * = V * X V Y . Finally, we set σ * = 1/V (U X ) * and calculate γ * = σ * Z * .
Validation of simulated summary statistics
We visually confirmed that the calculated Z E appeared sensible for one to four causal SNP models in a single region ( Figure S1 ). We next simulated data using our method or an individual-based method (HAPGEN+SNPTEST) for five scenarios (Table 1) , and observed that both the distributions of Z scores and log odds ratios were similar for both strategies, either for sample sizes of 1000 cases and 1000 controls or 5000 cases and 5000 controls, both at the causal variants ( Figure 1 ) and at variants in weak LD with them ( Figure S2 ). Note in particular the difference between scenarios 4 and 5. In scenario 4, two variants in weak LD each have a log odds ratio of log(1.2) = 0.18 or log(1/1.2) = −0.18. In this case, marginal estimate of odds ratios are close to these values, and Z scores are highly significant. In scenario 5, the pair of odds ratios are the same, but at strongly linked variants (r 2=0.8 ). This would be expected to cause the effect of one to be "cancelled" by the other in the marginal associations, so that estimates of log OR are attenuated towards 1 and significance is dramatically lower, as seen for both HAPGEN+SNPTEST and simGWAS simulations.
Finally, we compared simulation speed of each strategy as the number of causal variants, the number of samples and the number of replicates varied. For a region with 1000 SNPs using AFR data from 1000 Genomes (∼ 600 samples), both methods were very fast (< 30 seconds)
for the simplest scenario of 1000 cases and 1000 controls. We found that both methods required slightly, but negligibly, more time as the number of causal variants increased from one to six (Figure 2a ). As expected, HAPGEN+SNPTEST scaled linearly with either the number of replications or sample size, whereas simGWAS timings were independent of either factor (Figure 2b-c) . This emphasizes the potential for fast simulation of summary statistics for very large case-control datasets.
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Discussion
Simulating GWAS summary statistics in the context of case-control studies, for any required causal model and set of odds ratios, has several potential applications. Primarily, simulated GWAS results have become the accepted gold standard for validating newly developed statistical models for the analysis of GWAS data. Our intent is to enable the faster simulation of summary statistics compared to individual level data simulation, while at the same time using considerably less disk space.
In addition to supporting method development, simulation of GWAS statistics is also used in tests aggregating information across sets of SNPs, e.g. for pathway analysis. Pathway analysis can test either the global null, of no association between any SNP and phenotype, or the competitive null, which assumes there are some truly associated SNPs, but that these are randomly distributed amongst the sets of SNPs considered (i.e. those near genes in or out of the pathway under test, or those corresponding to presence or absence of a feature of interest). The second seems more appropriate, because it acknowledges that enrichment tests are performed in the context of genome-wide significant associations having been already found. However, the second is also much harder to simulate.
A common technique for simulating under a competitive null is permutation testing; the underlying dataset is maintained, and labels are permuted to generate new datasets where traits are still associated, but there is no possible correlation to the feature of interest. However, doing this so as not to destroy the genomic structure within the region, can require inventive generation of null distributions, for example, by circularisation and permutation of genomic features to allow empirical null distributions to be calculated under a competitive null (Trynka et al., 2015) . While these are efficient, they can only be used for features that span shorter distances than LD -e.g. for chromatin mark enrichment but not genes collected in pathways. 
Methods
Simulations to validate summary statistics
We evaluated our proposed method by simulating summary statistics in parallel using simGWAS (our method) and the same settings with HAPGEN2 + SNPTEST2, using refer- Two causal variants, weakly linked (r=0.15, odds ratios 1.2 and 1/1.2) 5
Two causal variants, strongly linked (r=0.8, odds ratios 1.2 and 1/1.2) Let there be a total of N samples selected, with N 1 having been chosen from disease cases (Y i = 1) and N 0 having been chosen from disease controls (Y i = 0). Since this sampling is conditional upon case/control status, genotype frequencies may differ between our N samples and the whole population at disease associated SNPs. We therefore need to distinguish between which datasets the genotype probabilities are from; write P sam for probabilities computed for the samples (i.e. P sam (Y i = 1) = N 1 N ), and P for probabilities generated with reference to the whole population.
Let n be the total number of SNPs. For any SNP X, write G X i for its genotype coding ∈ {0, 1, 2} at sample i .
For the commonly used Cochran-Armitage test, the Z-Score at SNP X is computed as:
and V X , V Y are the variance of G X and Y respectively:
Under the null hypothesis of no association at SNP X, Z X is distributed as a standard normal. Hence the two-sided p-value at X is given by:
where Φ is the cumulative distribution function of the standard normal distribution. Conversely, given the unsigned p-value at X, the absolute value of the Z-Score is:
Allelic frequencies under a Causal Model
Write W = W 1 , ..., W m for the vector of causal SNPs. From phased publicly available reference datasets such as UK10K (Walter et al., 2015) , it is possible to estimate haplotype frequencies across all SNPs in W at any subset of potential causal SNPs in control datasets.
Since they are causal, these frequencies will differ in cases, and it is those frequencies we derive first. Note that, since sampling dependent only upon case/control status, we can assume:
Write γ 1 , ..., γ m for the log odds ratios of effect for the causal SNPs in the population. We assume that Y given G W can be modelled as a binomial logistic regression. Then, from (Prentice and Pyke, 1979) , the sample-specific odds ratios are the same as those at the population-level, and we can write:
where γ 0 is an intercept parameter. Since GWAS sampling is retrospective, the proportion of cases in the sample is fixed at N 1 N , constraining γ 0 , which can be computed as follows:
Hence we can compute:
And also:
To derive genotype probabilities at SNPs in LD with the causal SNPs, we assume that LD structures do not differ between cases and controls, and hence the correlation between W and X is independent of both disease status and our sampling. Thus:
21 and we can estimate, for both the whole population, and for our sample:
from our reference dataset, for any constant a. From this, we compute:
By expanding out the numerator in terms of probabilities within the sample dataset, we see that:
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And hence:
Estimation of Z Score for the causal model given by W and γ
Finding the true expectation of U X √ V is intractable, so instead we compute a first order approximation by assuming independence:
These terms can be computed as shown in the following sections.
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Estimation of U X , the covariance between G X and Y , for the causal model given by W and γ
We compute the expectation of U X in our sample as follows:
Using the expressions for E sam (G X i |Y i ) given in Section, this becomes:
Estimation of V X , the variance of G X , for the causal model given by W and γ Recall:
This is tractable, however, we need to find E 1 √ V X , which is more complex.
V X is the variance of a normal, and so we model it as an Inverse Gamma (α, β) distribution.
Then V −1 X has a Γ(α, β −1 ) distribution, and V −1 X has a generalised gamma distribution with parameters p = 2, d = 2α, a = β −1 . If V X ∼ Inverse Gamma (α, β) , then
Assuming we have computed E sam (V X ) and E sam (V 2 X ), α and β are completely specified as:
may be simply computed using:
. Breaking this down into terms, for (i, j, k, l) representing different indices, we have:
Giving:
Summary
Thus, given only a choice of which SNPs are causal (W), their effect sizes (γ), sample sizes (N 0 , N 1 ) and a reference dataset from which we can derive allele frequencies (E(G X i |Y i = 0)) and the relationships between SNPs (E(G X i |G W i = w)), we can derive an expected Z Score, Z EXP at any SNP, causal or not.
This can then be used directly. However, most applications require simulated output from such a GWAS. Z SIM can therefore be computed, which will be distributed:
where Σ is the genotype correlation matrix for the SNPs in this regionBurren et al. (2014) .Figure S1 : Local Manhattan plots for p values generated from expected Z scores under different scenarios, in order to confirm by visual inspection that the expected Z Scores produced by our algorithm are consistent with the behaviour we would expect from their causal SNPs. In order to easily see the pattern of association, causal variants chosen were common, with a strong effect and (in the case of multiple causal variants) only weakly linked. Figure S2 : Results from simGWAS are similar to those from HAPGEN+SNPTEST at SNPs unlinked to the simulated causal variants. Distributions of simulated Z scores (a-b) and log odds ratios (c-d) from HAPGEN+SNPTEST (top line in each pair, "HG") and simGWAS (bottom line "sG") for single and multi-SNP models under five scenarios, described in Table 1 . The sample size (n) is the number of cases and controls -i.e. n=1000 indicates the simulations related to 1000 cases and 1000 controls. The label of each plot gives the corresponding "scenario-snp" pair -i.e. the label 3-1 refers to scenario 3, first causal SNP. We chose a SNP in r 2 < 0.1 with any causal variant to show that simulated results at non-causal are also valid. 30
